|1.||Liu, Siyu: 3 articles (01/2006 - 03/2002)|
|2.||Hayden, Frederick G: 3 articles (11/2005 - 03/2002)|
|3.||Webster, A D B: 3 articles (01/2005 - 01/2003)|
|4.||Chaudhuri, A: 2 articles (08/2010 - 05/2005)|
|5.||Steiner, I: 2 articles (08/2010 - 05/2005)|
|6.||Sainio, K: 2 articles (08/2010 - 05/2005)|
|7.||Salonen, O: 2 articles (08/2010 - 05/2005)|
|8.||Kennedy, P G E: 2 articles (08/2010 - 05/2005)|
|9.||Budka, H: 2 articles (08/2010 - 05/2005)|
|10.||Koskiniemi, M: 2 articles (08/2010 - 05/2005)|
02/01/2001 - "Lastly, pleconaril has demonstrated efficacy in the treatment of severe life-threatening enteroviral infections of the newborn and in immunosuppressed individuals. "
01/01/2000 - "These data support the safety and efficacy of pleconaril in decreasing the signs and symptoms and viral shedding associated with a viral respiratory infection."
03/01/2002 - "Among the subset of subjects with proven picornaviral infection in both studies (42% of total enrolled), pleconaril 400 mg three-times daily (n = 323) reduced the time to alleviation of illness (no rhinorrhoea and other symptoms mild or absent for > or = 48 h) compared with placebo (n = 264) (median: 10.0 days for placebo and 8.5 days for pleconaril; P = 0.029). "
09/01/2000 - "Our data appear to support the use of a 5.0-mg/kg dose given every 8 to 12 h in future studies of pleconaril in neonatal patients with enteroviral infection."
03/01/1999 - "Thus, our data support the evaluation of a 5-mg/kg twice-daily oral dose of pleconaril for therapeutic trials in pediatric patients with enteroviral infections."
04/01/2003 - "This study evaluated the pharmacokinetics, safety and efficacy of pleconaril in infants with EV meningitis. "
07/16/2001 - "Pleconaril has some activity against enteroviruses and is available for compassionate use in meningitis; it also shows some efficacy against rhinoviruses in ongoing trials, but is not available for routine clinical use. "
04/01/2003 - "Double blind placebo-controlled trial of pleconaril in infants with enterovirus meningitis."
07/01/2006 - "Enteroviral meningitis: natural history and outcome of pleconaril therapy."
11/01/2003 - "Pleconaril for infantile enterovirus meningitis."
11/27/1999 - "EARLY TRIALS WITH PLECONARIL: Pleconaril is active against picomaviruses and appears to have interesting efficacy against exceptionally severe enterovirus infections. "
07/01/2006 - "Of 607 randomized patients in a multicenter, double-blind placebo-controlled study of pleconaril (200 mg three times daily versus an identical-appearing placebo), 240 patients were confirmed to have enterovirus infection. "
03/01/2015 - "Pleconaril is a capsid inhibitor used previously to treat enterovirus infections. "
01/15/2001 - "Pleconaril was used on a compassionate-release basis to treat patients with potentially life-threatening enterovirus infections, and for 38 of these patients sufficient follow-up data were available for determining responses to therapy. "
01/15/2001 - "Treatment of potentially life-threatening enterovirus infections with pleconaril."
|4.||Human Influenza (Influenza)
01/01/2012 - "In-Silico screening of Pleconaril and its novel substituted derivatives with Neuraminidase of H1N1 Influenza strain."
01/01/2012 - "Pleconaril variants with F, Cl, Br, CH3, OH and aromatic ring substitutions were shown to be effective alternatives to Oseltamivir as anti influenza drugs."
11/01/2013 - "This review highlights ten "hot topics" in current antiviral research: (i) new nucleoside derivatives (i.e., PSI-352938) showing high potential as a direct antiviral against hepatitis C virus (HCV); (ii) cyclopropavir, which should be further pursued for treatment of human cytomegalovirus (HCMV) infections; (iii) North-methanocarbathymidine (N-MCT), with a N-locked conformation, showing promising activity against both α- and γ-herpesviruses; (iv) CMX001, an orally bioavailable prodrug of cidofovir with broad-spectrum activity against DNA viruses, including polyoma, adeno, herpes, and pox; (v) favipiravir, which is primarily pursued for the treatment of influenza virus infections, but also inhibits the replication of other RNA viruses, particularly (-)RNA viruses such as arena, bunya, and hanta; (vi) newly emerging antiarenaviral compounds which should be more effective (and less toxic) than the ubiquitously used ribavirin; (vii) antipicornavirus agents in clinical development (pleconaril, BTA-798, and V-073); (viii) natural products receiving increased attention as potential antiviral drugs; (ix) antivirals such as U0126 targeted at specific cellular kinase pathways [i.e., mitogen extracellular kinase (MEK)], showing activity against influenza and other viruses; and (x) two structurally unrelated compounds (i.e., LJ-001 and dUY11) with broad-spectrum activity against virtually all enveloped RNA and DNA viruses."
04/01/2002 - "This includes, for the treatment of HIV infections, virus adsorption inhibitors (cosalane derivatives, cyanovirin-N), co-receptor antagonists (TAK-779, AMD3100), viral fusion inhibitors (pentafuside T-20, betulinic acid derivatives), viral uncoating inhibitors (azodicarbonamide), nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs: emtricitabine, amdoxovir, dOTC, d4TMP prodrugs, tenofovir disoproxil fumarate), non-nucleoside reverse transcriptase inhibitors (NNRTIs: thiocarboxanilide UC-781, capravirine, SJ-3366, DPC 083, TMC 125/R165335), integrase inhibitors (diketo acids), transcription inhibitors (temacrazine, flavopiridol), protease inhibitors (atazanavir, mozenavir, tipranavir); for the treatment of RSV and paramyxovirus infections, viral fusion inhibitors (R170591, VP-14637, NMS03); for the treatment of picornavirus infections, viral uncoating inhibitors (pleconaril); for the treatment of pesti- (hepaci-, flavi-) virus infections, RNA replicase inhibitors (VP-32947); for the treatment of herpesvirus (HSV, VZV, CMV) infections, DNA polymerase inhibitors (A-5021, L- and D-cyclohexenylguanine); for the treatment of VZV infections, bicyclic furopyrimidine analogues; for the treatment of CMV infections, fomivirsen; for the treatment of DNA virus infections at large (papilloma-, polyoma-, herpes-, adeno- and poxvirus infections), cidofovir; for the treatment of influenza, neuraminidase inhibitors (zanamivir, oseltamivir, RWJ-270201); for the treatment of HBV infections, adefovir dipivoxil; for the treatment of HBV and HCV infections, N-glycosylation inhibitors (N-nonyl-deoxynojirimycin); and, finally, IMP dehydrogenase inhibitors and S-adenosylhomocysteine hydrolase inhibitors, for the treatment of various virus infections, including hemorrhagic fever virus infections."
|5.||Encephalitis (Encephalitis, Rasmussen)
10/01/2007 - "In addition, treatment with pleconaril may have affected the severity of the encephalitis. "
08/01/2010 - "Ganciclovir and foscarnet can be given to treat cytomegalovirus encephalitis, and pleconaril for enterovirus encephalitis (IV class evidence). "
05/01/2005 - "Acyclovir might also be effective for varicella-zoster virus encephalitis, gancyclovir and foscarnet for cytomegalovirus encephalitis and pleconaril for enterovirus encephalitis (IV class of evidence). "
|8.||Secretory Immunoglobulin A (SIgA)